Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said

You may also be interested in...



Paxil Franchise In Peril After FDA Seizure

FDA's seizure of Paxil CR threatens about 90% of GlaxoSmithKline's remaining Paxil franchise sales in the U.S

House Energy & Commerce Committee Opens Vioxx Investigation

The House Energy & Commerce Committee has opened its investigation into the withdrawal of Vioxx with letters to FDA and Merck

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Topics

UsernamePublicRestriction

Register

PS061879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel